Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours

British Journal of Surgery

Volumn 100, Issue 1, 2013, Pages 5-14

  Waddell, T ^a   Cunningham, D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADJUVANT THERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; PREMEDICATION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PREMEDICATION; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84870941575     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8987     Document Type: Review

References (59)

1. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
2. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.,; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
3. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
4. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al.,; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
5. Bear HD, Tang G, Rastogi P, Geyer, CE Jr, Robidoux A, Atkins JN, et al., Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
6. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al., Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735-740.
7. Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC, et al., Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 2010; 183: 1317-1323.
8. Hellenthal NJ, Underwood W, Penetrante R, Litwin A, Zhang S, Wilding GE, et al., Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010; 184: 859-864.
9. Gorin MA, Ekwenna O, Soloway MS, Ciancio G,. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology 2012; 79: e11.
10. von Klot C, Becker JU, Grünwald V, Peters I, Kuczyk MA, Merseburger AS,. [Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney.] Aktuelle Urol 2012; 43: 337-339.
11. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, et al., Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28: 1502-1507.
12. Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI,. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol 2011; [Epub ahead of print].
13. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M,; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
14. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al., Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
15. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
16. Sbitti Y, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, et al., Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol 2011; 9: 112.
17. Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT,. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol 2010; 3: 31.
18. National Institutes of Health. A Service of the U.S. National Institutes of Health; 2012. http://www.clinicaltrials.gov [accessed 05 September 2012].
19. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, et al., Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-631.
20. Rubin BP, Fletcher JA, Fletcher CD,. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol 2000; 8: 5-10.
21. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
22. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al., Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
23. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
24. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al., Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
25. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al.,; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
26. Casali PG, Blay JY,; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v98-v102.
27. Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al., Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19: 1074-1080.
28. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al., Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma; 2012. www.nccn.org/professionals/ physician-gls/pdf/sarcoma.pdf (accessed 05 September 2012).
30. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
31. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al., Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-1627.
32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.,; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
33. Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J, et al., Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int 2011; 31: 740-743.
34. Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B, et al., Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol 2011; 79: 1013.
35. Truesdale AE, Caldwell SH, Shah NL, Argo CK, Al-Osaimi AM, Schmitt TM, et al., Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011; 24: 991-998.
36. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al.,; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
37. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, et al., Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010; 116: 5599-5607.
38. Boeck SH, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, et al., Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): translational analyses of a randomized, cross-over AIO phase III trial. J Clin Oncol 2011; 29 (Suppl): 4047. Meeting abstract.
39. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al., Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-503.
40. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610.
41. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
42. Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, et al., Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2012; [Epub ahead of print].
43. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al., Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
44. Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, et al., Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009; 100: 1842-1845.
45. Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, et al., Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011; 68: 1431-1438.
46. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al., Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008; 371: 2101-2108.
47. Kim ST, Lim do H, Jang KT, Lim T, Lee J, Choi YL, et al., Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 2011; 10: 1993-1999.
48. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al., A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048.
49. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al., Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
50. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
51. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, et al., Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038.
52. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
53. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes RL, Barugel ME, et al., Final results from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 2011; 29 (Suppl): abstract 3510.
54. Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, et al., Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111.
55. Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, et al., Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-408.
56. Firek P, Richter S, Jaekel J, Brehmer B, Heidenreich A,. [Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors.] Urologe A 2012; 51: 398-402.
57. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al., Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012; 19: 2547-2555.
58. Leung AM, Hari DM, Morton DL,. Surgery for distant melanoma metastasis. Cancer J 2012; 18: 176-184.
59. Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, et al., Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Int J Clin Oncol 2011; 16: 741-745.